Q&A with Daniel Drucker

2024-9-1

Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease

2024-9-1

EGFR-mutated NSCLC: A roadmap to treatment sequences

2024-9-1

Shaping the future of heart health

2024-9-1

Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma

2024-9-1

How to rescue a DreaMM deferred …

2024-9-1

The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

2024-9-1

Ticagrelor monotherapy in ST-elevation myocardial infarction: An individual patient-level meta-analysis from TICO and T-PASS trials

2024-8-1

Zinc for GNAO1 encephalopathy: Preclinical profiling and a clinical case

2024-8-1

Association between situs inversus and maternal SARS-CoV-2 infection at gestational age 4–6 weeks

2024-8-1

The common p.Ile291Val variant of ERLIN1 enhances TM6SF2 function and is associated with protection against MASLD

2024-8-1

Accelerating drug discovery, development, and clinical trials by artificial intelligence

2024-8-1

Unraveling the physiological and psychosocial signatures of pain by machine learning

2024-8-1

Rising incidence of obesity-related cancers among younger adults in China: A population-based analysis (2007–2021)

2024-8-1

Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer

2024-8-1

Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial

2024-8-1

Preclinical assessment for translation to humans: The PATH approach for assessing supporting evidence for early-phase trials and innovative care

2024-8-1

Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes

2024-8-1

PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial

2024-8-1

Large-scale pretrained frame generative model enables real-time low-dose DSA imaging: An AI system development and multi-center validation study

2024-8-1

Socioeconomic characteristics, cancer mortality, and universal health coverage: A global analysis

2024-8-1

Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer

2024-8-1

Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia

2024-8-1

Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed

2024-8-1

Bilirubin metabolism in early life and respiratory health during preschool age: A combined analysis of two independent birth cohorts

2024-8-1

Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease

2024-8-1

Storage, preservation, and rehabilitation of living heart valves to treat congenital heart disease

2024-8-1

Opportunities and challenges for immunosuppression in the context of pig-to-human xenotransplantation

2024-8-1

Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study

2024-8-1

COX inhibition with anti-PD-1 in advanced dMMR colorectal cancer: Improving antigen presentation?

2024-8-1

Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC

2024-8-1

Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?

2024-8-1

Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050

2024-8-1

Impact of omega-3 fatty acids on hypertriglyceridemia, lipidomics, and gut microbiome in patients with type 2 diabetes

2024-8-1

Functional modification of gut bacteria for disease diagnosis and treatment

2024-7-3

NanoRanger enables rapid single-base-pair resolution of genomic disorders

2024-7-1

Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial

2024-7-1

Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer

2024-7-1

Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial

2024-7-1

Adding first-line PD-1 inhibition to anti-VEGF and XELOX in pMMR metastatic colorectal cancer: Steppingstones, stumbling blocks, and next phase

2024-7-1

Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses

2024-7-1

Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer

2024-7-1

Exploiting the potential of dupilumab in the treatment of eosinophilic COPD

2024-7-1

Global burden and management of women with epilepsy in pregnancy: A modeling study

2024-7-1

Exceptional, naturally occurring HIV-1 control: Insight into a functional cure

2024-7-1

ALINA: Another stepping stone toward a future of LDCT lung cancer screening in never-smokers?

2024-7-1

A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral T cell lymphoma

2024-7-1

Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: A cluster analysis based on CSTAR cohort

2024-7-1

Cancer research is not correlated with driver gene mutation burdens

2024-7-1

A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer

2024-7-1